BM32 is developed by Biomay AG.

What development phase is BM32 in?

BM32 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

BM32

Biomay AG · FDA-approved active Biologic Quality 4/100

BM32, marketed by Biomay AG, is a therapeutic agent with a key composition patent expiring in 2028. The drug's mechanism of action involves interacting with a specific biological target, providing a unique therapeutic effect that distinguishes it in the market. The primary risk facing BM32 is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Generic name	BM32
Sponsor	Biomay AG
Modality	Biologic
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response (PHASE2)
Phase II Study of Grass Pollen Allergy Vaccine BM32 (PHASE2)
Skin Test Study of BM32 (PHASE1,PHASE2)
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results